First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

NCT04504669 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear Cell Renal Cell Cancer
Non-Small-Cell Lung Cancer
Triple Negative Breast Neoplasms
Squamous Cell Cancer of Head and Neck
Small Cell Lung Cancer
Gastroesophageal Cancer
Melanoma
Cervical Cancer
Advanced Solid Tumours

Interventions

DRUG: AZD8701
BIOLOGICAL: Durvalumab

Sponsor

AstraZeneca